Crohn's Disease and Ulcerative Colitis
Inflammatory bowel disease (IBD), comprising Crohn's disease and ulcerative colitis, emerges from intersecting genetic risk, environmental exposures, microbiota shifts, and mucosal immune dysregulation. This Reprint, "Crohn's Disease and Ulcerative Colitis: From Pathophysiology to Novel Therapeutic...
Furkejuvvon:
| Materiálatiipa: | Online |
|---|---|
| Giella: | eaŋgalasgiella |
| Almmustuhtton: |
MDPI - Multidisciplinary Digital Publishing Institute
2026
|
| Fáttát: | |
| Liŋkkat: | ONIX_20260416T142754_9783725863945_47 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|
| _version_ | 1869524860830482432 |
|---|---|
| collection | Directory of Open Access Books |
| description | Inflammatory bowel disease (IBD), comprising Crohn's disease and ulcerative colitis, emerges from intersecting genetic risk, environmental exposures, microbiota shifts, and mucosal immune dysregulation. This Reprint, "Crohn's Disease and Ulcerative Colitis: From Pathophysiology to Novel Therapeutic Approaches (2nd Edition)," integrates 18 peer reviewed articles that connect mechanisms to practice. Mechanism guided targets include epithelial barrier injury, innate immune and pyroptosis pathways, bile acid signaling, and candidate genes such as SLC26A2 with diagnostic and therapeutic relevance. Microbiome aware care spans mucosa associated dysbiosis, oral fungi and herpesviruses as extra intestinal reservoirs, dietary signals such as coffee consumption, and emerging interventions from refined fecal microbiota transplantation to next generation probiotics. Model informed therapeutics evaluate route and dose optimization with physiologically based pharmacokinetics for infliximab, external validation of vedolizumab population pharmacokinetic models, pharmacogenetic markers of biologic response, and comparative effectiveness of subcutaneous versus intravenous IL 12/23 blockade. Patient centered outcomes and complications are addressed through evidence on postoperative recurrence in Crohn's disease, extraintestinal manifestations including ocular involvement, and the role of acceptance and perceived control in health experience. A genetics study links IBD to related immune mediated diseases and identifies novel loci, sharpening paths to precision care. |
| format | Online |
| id | doab-20.500.12854ir-175342 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2026 |
| publishDateRange | 2026 |
| publishDateSort | 2026 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-1753422026-04-16T20:20:14Z Crohn's Disease and Ulcerative Colitis Long, Dingpei Inflammatory bowel disease Crohn&rsquo S disease Ulcerative colitis Pathophysiology Microbiome Bile acid signaling Pyroptosis thema EDItEUR::M Medicine and Nursing Inflammatory bowel disease (IBD), comprising Crohn's disease and ulcerative colitis, emerges from intersecting genetic risk, environmental exposures, microbiota shifts, and mucosal immune dysregulation. This Reprint, "Crohn's Disease and Ulcerative Colitis: From Pathophysiology to Novel Therapeutic Approaches (2nd Edition)," integrates 18 peer reviewed articles that connect mechanisms to practice. Mechanism guided targets include epithelial barrier injury, innate immune and pyroptosis pathways, bile acid signaling, and candidate genes such as SLC26A2 with diagnostic and therapeutic relevance. Microbiome aware care spans mucosa associated dysbiosis, oral fungi and herpesviruses as extra intestinal reservoirs, dietary signals such as coffee consumption, and emerging interventions from refined fecal microbiota transplantation to next generation probiotics. Model informed therapeutics evaluate route and dose optimization with physiologically based pharmacokinetics for infliximab, external validation of vedolizumab population pharmacokinetic models, pharmacogenetic markers of biologic response, and comparative effectiveness of subcutaneous versus intravenous IL 12/23 blockade. Patient centered outcomes and complications are addressed through evidence on postoperative recurrence in Crohn's disease, extraintestinal manifestations including ocular involvement, and the role of acceptance and perceived control in health experience. A genetics study links IBD to related immune mediated diseases and identifies novel loci, sharpening paths to precision care. 2026-04-16T20:20:01Z 2026-04-16T20:20:01Z 2026 book ONIX_20260416T142754_9783725863945_47 9783725863945 9783725863952 https://directory.doabooks.org/handle/20.500.12854/175342 eng application/octet-stream Attribution 4.0 International https://mdpi.com/books/ https://mdpi.com/books/pdfview/book/12257 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-7258-6395-2 10.3390/books978-3-7258-6395-2 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783725863945 9783725863952 330 CH open access |
| spellingShingle | Inflammatory bowel disease Crohn&rsquo S disease Ulcerative colitis Pathophysiology Microbiome Bile acid signaling Pyroptosis thema EDItEUR::M Medicine and Nursing Crohn's Disease and Ulcerative Colitis |
| title | Crohn's Disease and Ulcerative Colitis |
| title_full | Crohn's Disease and Ulcerative Colitis |
| title_fullStr | Crohn's Disease and Ulcerative Colitis |
| title_full_unstemmed | Crohn's Disease and Ulcerative Colitis |
| title_short | Crohn's Disease and Ulcerative Colitis |
| title_sort | crohn s disease and ulcerative colitis |
| topic | Inflammatory bowel disease Crohn&rsquo S disease Ulcerative colitis Pathophysiology Microbiome Bile acid signaling Pyroptosis thema EDItEUR::M Medicine and Nursing |
| topic_facet | Inflammatory bowel disease Crohn&rsquo S disease Ulcerative colitis Pathophysiology Microbiome Bile acid signaling Pyroptosis thema EDItEUR::M Medicine and Nursing |
| url | ONIX_20260416T142754_9783725863945_47 |